MK0524 Seasonal Allergic Rhinitis Study

This study has been completed.
Sponsor:
Information provided by:
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00533208
First received: September 19, 2007
Last updated: NA
Last verified: September 2007
History: No changes posted

September 19, 2007
September 19, 2007
December 2003
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
MK0524 Seasonal Allergic Rhinitis Study
Not Provided

To assess the efficacy of MK0524 on seasonal allergies.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Seasonal Allergies
Drug: MK0524
Not Provided
Philip G, van Adelsberg J, Loeys T, Liu N, Wong P, Lai E, Dass SB, Reiss TF. Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis. J Allergy Clin Immunol. 2009 Nov;124(5):942-8.e1-9. Epub 2009 Sep 12.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
December 2003
Not Provided

Inclusion Criteria:

  • Person has had at least 2 years of seasonal allergies
  • Person has had a positive skin test to at least 1 of the allergens of the season
  • Person is a non-smoker

Exclusion Criteria:

  • Person has been hospitalized within the last 4 weeks
  • Person is a female who has had a baby within the last 8 weeks or is still breast-feeding
Both
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00533208
2007_616
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
September 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP